Term ends Jan 3, 2035 · High confidence
20-year base term ends Mar 12, 2028
Held by GlaxoSmithKline LLC
Filed Mar 19, 2010 as application 12/530,610 · Granted Jul 16, 2013
Base term plus 662 days of patent term adjustment (USPTO delay)
Today
2008
2035
Clock starts
Mar 12, 2008
Mar 12, 2008
Term ends
Jan 3, 2035
Jan 3, 2035
Granted
Jul 16, 2013
Jul 16, 2013
base term
patent term adjustment
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
662
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 662 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 12, 2008, when application PCT/AU2008/000339, the earliest non-provisional in its chain, was filed (this one was filed Mar 19, 2010) | Mar 12, 2028 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +662 days, USPTO patent term adjustment record | Jan 3, 2030 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | +5 years, USPTO 35 U.S.C. 156 certificate | added to Jan 3, 2030: Jan 3, 2035 | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 3, 2035 | High confidence |
This family
| US 8,486,941 | this patent Jan 2035 | Jan 2035 |
| US 9,238,628 | In force Mar 2028 | Mar 2028 |
| US 9,233,934 | In force Jun 2028 | Jun 2028 |
| Application 14/960,710 | Abandoned not computed | not computed |
| US 12,570,614 | In force Mar 2028 | Mar 2028 |
| Application 19/459,164 | Pending not computed | not computed |
6 of 7 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 19, 2010 Reel 24110, frame 837 | Burns, Christopher John; Donohue, Andrew Craig; Feutrill, John Thomas; Nguyen, Thao Lien Thi; Wilks, Andrew Frederick; Zeng, Jun | Cytopia Research Pty Ltd. | Assignment of Assignor's Interest |
| Apr 15, 2010 Reel 24233, frame 869 | Cytopia Research Pty Ltd. | Ym Biosciences Australia Pty Ltd. | Change of Name |
| Oct 3, 2018 Reel 47059, frame 834 | Ym Biosciences Australia Pty Ltd. | Sierra Oncology, Inc. | Assignment of Assignor's Interest |
| May 26, 2023 Reel 63790, frame 568 | Sierra Oncology, Inc. | Sierra Oncology LLC | Change of Name |
| Jun 7, 2023 Reel 63879, frame 821 | Sierra Oncology LLC | GlaxoSmithKline LLC | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jan 2035
Term ends Jan 3, 2035. No further fees fall due before then
Note
The 662 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
83
later US patents cite this one
That is top 10% of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.